Head of Business Development
About the job
- At least 8 years of experience in pharmaceutical and/or diagnostics business development, either within a pharmaceutical company or at a diagnostics or technology company selling into pharma.
- A documented track record of leading or co-leading pharma deals in companion diagnostics, biomarkers, patient stratification, or similar; if not formally leading one, evidence of being pivotal in completing a deal.
- Experience building a pharma partnership pipeline from scratch or deciding from the pharma side which partnerships received funding.
- Fluency in how pharma makes partnership decisions, including decision-makers, business-unit budget ownership, and how deals are advanced.
- Existing relationships across large and mid-cap oncology pharma that can be activated.
- Comfort with deep technical material and a history of identifying non-obvious applications for it.
- Bias for action.
- Build Ataraxis's pharma partnership business from the ground up, owning pharma as a revenue stream alongside the diagnostics business.
- Identify target companies, map the decision unit within each, conduct outreach, and lead negotiations through signature.
- Construct applications of the technology against each company's development pipeline and translate them for scientific, clinical, and business audiences.
- Build and maintain relationships with pharma stakeholders who sponsor and fund partnerships.
- Bring pharma priorities and unmet needs back to research and product teams.
- Work with research, clinical, product, and legal teams to scope commitments, structure terms, and execute agreements.
- Work directly with the CEO on pipeline, forecast, and deal strategy.
- MD, PhD, PharmD, NP, or a Master’s degree in cancer biology, molecular biology, cell biology, biomedical sciences, pharmacology, pharmaceutical sciences, or a related life sciences field.
About the company
Ataraxis.ai creates precision medicine tools for cancer care using artificial intelligence. Its first product, Ataraxis Breast, is an AI-native prognostic test for breast cancer designed to predict patient outcomes more accurately and help doctors personalize treatment plans. Results are delivered quickly, within one business day, through a physician portal or to clinicians. The company differentiates itself by offering an AI-driven prognostic test that aims to set a new standard in molecular diagnostics rather than relying on traditional methods alone, with a focus on rapid, actionable insights for oncology. The goal is to improve how cancer treatment decisions are made by providing fast, data-driven prognostic information to physicians and healthcare providers.
Company Size
11-50
Company Stage
Series A
Total Funding
$44.8M
Headquarters
New York City, New York
Founded
2023
Get referred to Ataraxis.ai
See people who can refer or advise you
Simplify's Take
What believers are saying
- Ataraxis launched ARC in 2026, creating prospective evidence for broader commercialization.
- California licensure and CAP accreditation expanded access for clinicians and patients statewide.
- The $20.4 million Series A funded breast test launch and expansion into solid tumors.
What critics are saying
- Exact reimbursement remains undisclosed, so 2026 revenue depends on clinician adoption and self-pay demand.
- Tempus and Foundation Medicine already own oncology workflows, pressuring Ataraxis's sales cycle.
- If Breast test performance disappoints in prospective ARC studies, Ataraxis loses its entire platform thesis.
What makes Ataraxis.ai unique
- Ataraxis Breast uses causal multimodal AI, not generic pathology scoring, across CTX and NEO.
- The platform validated on TAILORx, UNIRAD, and 11,135 patients across 17 cohorts.
- CAP-accredited, California-licensed laboratory delivery makes Ataraxis a regulated, clinic-ready diagnostics vendor.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Company Equity